CCS
XPH icon

Crosspoint Capital Strategies’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Crosspoint Capital Strategies’s Portfolio XPH Stock Details XPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-720
Closed -$78K – 843
2015
Q4 		$78K Buy
+720
New +$36.7K 0.02% 374

Other funds holding XPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
KHLMVGHM
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $1.53B AUM 20.88% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Crosspoint Capital Strategies's XPH Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2016, closing a stake of 720 shares — an estimated $78K sold.

Crosspoint Capital Strategies first reported a position in XPH in Q4 2015 and held it in 1 quarter. The position peaked at $78K in Q4 2015. 71 funds tracked by Wall St. Rank hold XPH as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 720 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2016, an estimated $78K.
  • Crosspoint Capital Strategies first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's State Street SPDR S&P Pharmaceuticals ETF position peaked at $78K in Q4 2015.
  • 71 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.